These data suggest that PTPN3 is an oncogene that promotes drug resistance and stem cell-like characteristics in ovarian cancer, and thus it is a potential therapeutic target for the treatment of ovarian cancer. This evidence concerns the gene PTPN3 and ovarian carcinoma.